Company news
Plus Therapeutics, Inc. news in 2023
Plus Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.
Plus Updates Financial and Cash Guidance for 2024
December 17, 2023
Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses
December 11, 2023
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar
November 19, 2023
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases
November 2, 2023
Plus Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
October 30, 2023
Plus Therapeutics Announces Share Repurchase Program
October 30, 2023
Plus Therapeutics to Announce Third Quarter 2023 Financial Results and Host Conference Call on October 31, 2023
October 22, 2023
Plus Therapeutics Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium (¹⁸⁶Re) Obisbemeda in Leptomeningeal Metastases
October 9, 2023
Plus Therapeutics Enters into License Agreement for Cerebrospinal Fluid Tumor Cell Enumeration Assay
September 7, 2023
Plus Therapeutics Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase
September 4, 2023
Plus Therapeutics Announces Key Opinion Leader Roundtable on New Clinical Trial Data Being Presented at the 2023 SNO/ASCO CNS Cancer Conference
August 7, 2023
Plus Therapeutics Strengthens Clinical Program with the Appointment of Pius Maliakal as Vice President of Clinical Operations
July 26, 2023
Plus Therapeutics Reports Positive Interim Updates from Two ReSPECT™ Clinical Trials at SNMMI Annual Meeting
June 28, 2023
Plus Therapeutics Announces Participation at Upcoming SNO Pediatric Conference and SNMMI Annual Meeting
June 7, 2023
Plus Therapeutics Provides Company Update Today
May 31, 2023
Plus Therapeutics Announces Topline Results from Recurrent Glioblastoma External Control Analysis at ASCO 2023
May 29, 2023
Plus Therapeutics Regains Compliance with Nasdaq Listing Requirements
May 15, 2023
Plus Therapeutics Expands Collaboration with Piramal Pharma Solutions to Meet Increase in Investigational Drug Demand for Ongoing and Planned Clinical Trials
May 1, 2023
Plus Therapeutics Announces Reverse Stock Split
April 27, 2023
Plus Therapeutics Completes Phase 1/Part A of the ReSPECT-LM Clinical Trial for Leptomeningeal Metastases
April 17, 2023
Plus Therapeutics Successfully Treats First Patient in Cohort 8 of ReSPECT-GBM Phase 1/2a Trial
March 27, 2023
Plus Therapeutics Initiates Cohort 3 in Phase 1/Part A of the ReSPECT-LM Trial for Leptomeningeal Metastases
March 21, 2023
Plus Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
February 22, 2023
Plus Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on February 23, 2023
February 13, 2023
Plus Therapeutics Completes Enrollment in Second ReSPECT-LM Phase 1 Trial Cohort of Rhenium (¹⁸⁶Re) Obisbemeda for the Treatment of Leptomeningeal Metastases
January 31, 2023
Plus Therapeutics Announces First Patient Dosed in ReSPECT-GBM Phase 2b Trial of Rhenium (186Re) Obisbemeda for Treatment of Recurrent Glioblastoma
January 17, 2023
Calls in 2023
- PLUS THERAPEUTICS (NASDAQ:PSTV) Q3 2023 Earnings Call
Oct 31, 2023
Transcript - PLUS THERAPEUTICS (NASDAQ:PSTV) Q2 2023 Earnings Call
Aug 14, 2023
Transcript - PLUS THERAPEUTICS (NASDAQ:PSTV) Q1 2023 Earnings Call
Apr 20, 2023
Transcript - PLUS THERAPEUTICS (NASDAQ:PSTV) Q4 2022 Earnings Call
Feb 23, 2023
Transcript